Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alzamend Neuro, Inc., a Delaware corporation and emerging growth company, on July 21, 2026. The report discloses a material event under Item 8.01 (Other Events) regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the passing of Lynne Fahey McGrath, M.P.H., Ph.D., a member of the Company's Board of Directors, on July 20, 2026. Dr. McGrath had served on the Board since the Company's initial public offering in June 2021.
Management Commentary and Risks
William B. Horne, Chairman of the Board, issued a statement expressing profound sadness over Dr. McGrath's sudden passing. He described her as a passionate director who prioritized the Company's needs, provided significant biopharmaceutical knowledge, and was irreplaceable. The filing does not disclose specific financial risks, contingencies, or unusual items related to operations.
Key Facts for Investor Verification
- Dr. Lynne Fahey McGrath passed away on July 20, 2026.
- Dr. McGrath was a director since the IPO in June 2021.
- The Board has lost a member with significant biopharmaceutical expertise.
- Investors should monitor future filings for the appointment of a replacement director.